Norbert Riedel

Norbert G.
Riedel was the founder of Aptinyx, Inc., founded in 2015, where the title held was Executive Chairman from 2022 to 2023.
Current jobs include Chairman at Eton Pharmaceuticals, Inc. since 2018; Director at Jazz Pharmaceuticals, Inc. since 2013; Director at Illinois Biotechnology Industry Organization since 2001; Director at Atsena Therapeutics, Inc.; Independent Director at Jazz Pharmaceuticals Plc since 2013; Director at TRACT Therapeutics, Inc.; Director at Cerevel Therapeutics LLC since 2018; Director at Illinois Biotechnology Innovation Organization; Director at Cerevel Therapeutics, Inc.; Operating Partner at Beecken Petty O'Keefe & Co. LP; Trustee at Chicago Symphony Orchestra Association; Member at Osterreichische Akademie Der Wissenschaften since 2009; Member-Supervisory Board at Zytoprotec GmbH; Adjunct Professor at Feinberg School of Medicine; Member at Austrian Academy of Sciences since 2009; Industry Advisor at Agent Capital LLC; and chief scientific officer at Baxter Ventures.
Former jobs include President, Chief Executive Officer & Director at Naurex, Inc. from 2014 to 2015; Vice Chairman-Supervisory Board at MediGene AG from 2003 to 2013; Director at Oscient Pharmaceuticals Corp.
from 1999 to 2010; Independent Director at ARIAD Pharmaceuticals, Inc. from 2011 to 2017; Director at Genencor International, Inc.; Lead Independent Director at Cerevel Therapeutics Holdings, Inc. from 2018 to 2024; Chief Scientific & Innovation Officer at Baxter International, Inc. from 2011 to 2013; Principal at Hoechst AG; Vice President-Research & Development at Baxter BioScience Corp.
from 1998 to 2001; Head-Worldwide Biotechnology at Hoechst Marion Roussel, Inc. from 1996 to 1998; and Associate Professor at Boston University School of Medicine from 1987 to 1991.
Education includes undergraduate and doctorate degrees from Johann Wolfgang Goethe-Universität Frankfurt am Main, with the doctorate conferred in 1983.